A paradigm shift in heart failure treatment?

May 26, 2018

Vienna, Austria - 26 May 2018: A small, preliminary study could trigger a paradigm shift in the treatment of heart failure. The late-breaking research is published today in Circulation and presented at Heart Failure 2018 and the World Congress on Acute Heart Failure, a European Society of Cardiology congress.1,2 The study suggests that heart failure may be caused by inappropriate fluid shifts in some patients rather than an excess of fluid.

Heart failure is a global pandemic affecting at least 26 million people worldwide and is increasing in prevalence. Despite the significant advances in therapies and prevention, mortality and morbidity are still high and quality of life poor.3

It is currently believed that heart failure is caused by excess salt and fluid in the heart and lungs. However, 50% of patients with acute heart failure do not have fluid overload when they present to hospital.

In these patients, an alternative mechanism could be that fluid has been inappropriately redistributed from the abdominal (splanchnic) compartment to the heart and lungs. It is thought that this leads to increased pressure in the heart, resulting in impaired heart function (decompensation). It has been proposed that this redistribution is partly caused by overactivity of the splanchnic nerves, which cause the vasculature in the belly to constrict.4

This first proof of concept study in humans sought to prove that this fluid redistribution exists in patients with acute heart failure and could be a target for treatment. The study included five patients with acute heart failure admitted to Duke University Hospital in Durham, North Carolina, US.

Splanchnic nerve block was performed by injecting lidocaine on either side of the spine under X-ray guidance. This is an established procedure that is used to relieve abdominal pain in patients with pancreatic and duodenal cancer. Right heart catheterisation was conducted to measure pressures in the heart and pulmonary artery.

Following lidocaine injection, pressures in the right and left side of the heart and pulmonary artery reduced rapidly, suggesting that blood shifted from the heart and lungs to the belly. The reduction in pressures began 15-20 minutes after the nerve block and reached the maximum effect at 30 minutes. Pressures mostly returned to starting levels at 90 minutes, which is the expected duration of lidocaine action. There were no adverse events.

Before and after the procedure, patients performed a six-minute walk test and were asked about shortness of breath, a typical heart failure symptom. Both measures improved, but the differences were only statistically significant for the shortness of breath questionnaires, likely due to the small number of patients.

Principal investigator Dr Marat Fudim, of Duke Clinical Research Institute, said: "This study supports the notion that volume redistribution is a cause of heart failure. When the splanchnic nerve is blocked, the belly vasculature is no longer constricted and space is created. Fluid then shifts from the heart and lungs to the abdomen, where it should be. This normalises pressures in the heart and lungs and patients feel better."

Diuretics are a cornerstone of treatment in acute heart failure but often cause kidney damage. "This may be because these patients do not actually have extra fluid," said Dr Fudim. "Our study suggests that shifting fluid from the chest to the belly, instead of getting rid of fluid with diuretics, may be the appropriate treatment for some patients with acute heart failure."

Dr Fudim noted that the nerve block in this study was temporary. Future studies will need to examine the impact of longer-acting medications or even killing the splanchnic nerves. The latter has been used to alleviate pain in cancer patients. The nerve block will also need to be tested in patients with chronic heart failure.
-end-


European Society of Cardiology

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.